ArticleBMC cancer2026
Real-life data of patients with chronic myeloid leukemia in Amazonas.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundChronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the t(9;22)(q34;q11.2) translocation, known as the Philadelphia chromosome (Ph+), which generates the BCR::ABL1 fusion oncogene central to CML pathogenesis. The disease accounts for approximately 15% of adult leukemias, predominantly affects males, and has a median age at diagnosis of around 57 years. CML typically presents in the chronic phase and may progress to advanced disease phases, with prognostic risk stratification guiding treatment decisions. Tyrosine kinase inhibitors (TKIs) are the cornerstone of therapy, aiming to achieve durable molecular disease control and, in selected patients, sustained deep molecular response and treatment-free remission. This study evaluated the demographic, clinical, and molecular response profiles of patients with Ph + CML treated with first- and second-line TKIs at the Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM).
methodsThis retrospective, longitudinal study analyzed medical records of 176 patients diagnosed with Ph + CML between 2011 and 2020. Demographic characteristics, clinical data, and laboratory findings were extracted from medical records. Longitudinal molecular response was assessed in patients with available BCR::ABL1 monitoring.
resultsAmong the 176 patients identified, 122 were included in the analysis of treatment outcomes. The mean age at diagnosis was 49.6 years, with a slight male predominance. Most patients were diagnosed in the chronic phase, and high-risk Sokal score was the most frequent prognostic category among evaluable cases. The e14a2 (b3a2) transcript was the most prevalent molecular subtype. Clinically meaningful molecular responses were observed in both first- and second-line treatment settings, although response assessment was influenced by real-world constraints, including incomplete molecular monitoring and heterogeneous follow-up.
conclusionsThese findings provide real-world insights into the epidemiological, clinical, and molecular response characteristics of Ph + CML patients treated in the Amazon region. The study highlights the challenges of implementing guideline-based molecular monitoring in geographically constrained settings and supports the need for adapted strategies to optimize long-term CML management in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.